| Factor Information | |
|---|---|
| Data ID | 318 |
| Factor | VWF:Ag with sildenafil treatment |
| Description | N/A |
| Biomarker | NA |
| Classification | A6 (clinical factor - other) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | PAH-CHD patients |
| p Value | 0.019 |
| Conclusion | VWF:Ag improved transiently in the sildenafil group. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 101 |
| CHD Type | isolated CHD |
| CHD Subtype | CHD with PAH |
| Reference | |
|---|---|
| PMID | 30343508 |
| Year | 2019 |
| Title | Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease. |
| Sample | ||
|---|---|---|
| Population | Adolescents and adults | |
| Source | blood | |
| Region | Brazil, Sao Paulo | |
| Method | Student’s t test or the Mann- Whitney test | |
| Race | American | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | Sildenafil group(Treatment) | Tadalafil group(Control) |
| Number | 16 | 16 |
| Age | 26.6 years(17.4-40.0) | 18-50 years |
| Gender (Male: Female) | 7:9 | N/A |
| Marker Level | 120U/dl(98-138) | N/A |
